In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 375 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557	Technology appraisal guidance	TBC
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment	Health technology evaluation	21 August 2025
Transcatheter tricuspid valve implantation for tricuspid regurgitation	Interventional procedures guidance	4 March 2026
Transvenous embolisation for treating cerebrospinal fluid venous fistula associated with spontaneous intracranial hypotension	Interventional procedures guidance	25 March 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	TBC
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	25 February 2026
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]	Technology appraisal guidance	18 March 2026
Venglustat for treating gangliosidoses in people 2 years and over ID 6358	Technology appraisal guidance	TBC
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults	Interventional procedures guidance	15 October 2025
Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest	Interventional procedures guidance	15 October 2025
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	13 November 2025
Vosoritide for treating achondroplasia in people 4 months and over ID6488	Technology appraisal guidance	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]	Technology appraisal guidance	28 January 2026
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC

Results per page

10
25
50
All